YOUR CORONAVIRUS RESOURCE
COVID-19
We Offer qPCR, CLIA Accredited COVID-19 Testing NOW

xymbio™ was founded by experienced medical scientists and healthcare professionals to utilize industry leading equipment including the latest technologies from ThermoFisher and operates under the Emergency Use Authorization (EUA) guidance issued by the FDA and CAP and CLIA quality standards.

Early detection is possible by molecular assay as it detects the viral nucleic acid or virus, which can detect as early as exposure – meaning before infection has initiated in the body. According to the CDC symptoms may appear 2-14 days after exposure making early detection an important tool in the fight against the Coronavirus Pandemic.

Radically Changing Infectious Disease Care for Our Partners
Infectious Disease Care
Rapid Results

Industry leading testing turnaround times to accelerate patient recovery.

Infectious Disease Care
Molecular Diagnosis

Ability to identify pathogenic genotype with the highest sensitivity and specificity.

Infectious Disease Care
Antimicrobial Resistance

Identification of resistance genes can rapidly improve treatment and outcomes paradigms.

Infectious Disease Care
Comprehensive Panels

Easily identify complicated infections with multiple pathogenic and non-pathogenic micro-organisms.

Infectious Disease Care
Antimicrobial Stewardship

Rapid test results and highly precise diagnosis allows accurate targeting of ID with proper antibiotic or antimicrobial.

Infectious Disease Care
Actionable Information

Receive ID diagnosis and treatment plan including region specific data to help guide clinical decisions.

Infectious Disease Care
Eliminate Trial and Error

Reduce or perhaps eliminate trial and error diagnosis and medication or loss of valuable time in patient care.

Infectious Disease Care
Complex Biofilm Samples

More easily identify complex multi pathogenic and mixed biofilm samples.

Infectious Disease Care
Extreme Sensitivity and Specificity

Identification of resistance genes rapidly changes treatment and outcome paradigm.

The BUG BOX ©
Patient Specimen Collection Kit
the bug box
Infectious Disease Care
Coronavirus (COVID-19) qPCR Testing

Advanced multiplex testing technology which identifies the novel SARS CoV 2 virus, which is strain specific, for all known sub-strains

Capability to run higher test volumes in shorter periods of time at reduced cost per sample than other currently used technologies

Operates under the Emergency Use Authorization (EUA) guidance issued by the FDA and adheres to CAP and CLIA quality standards

INFECTIOUS DISEASE

RISK

U.S. RISK OF ANTIMICROBIAL RESISTANCE

23,000

U.S. Yearly Infectious Disease Deaths (CDC)

2,000,000

Antimicrobial-Resistant Infections (CDC)

30%

Unnecessary Antibiotics Prescribed (CDC)

INFECTIOUS DISEASE

COST

U.S. RISK OF ANTIMICROBIAL RESISTANCE

20

Billion $ Healthcare Spend (CDC)

35

Billion $ Lost Productivity (CDC)

8

Million Additional Hospital Days Spent (CDC)